Скачать или смотреть iNNOVATE trial of added ibrutinib for Waldenströms Macroglobulinemia

Dr Dimopolous presents results at EHA 23 from the iNNOVATE trial of rituximab with or without oral BTK-inhibitor ibrutinib to Waldenströms Macroglobulinemia.

He outlines the study design, with patients randomised 1:1 to receive ibrutinib or placebo orally until disease progression, and the improved progression-free survival of those patients receiving the added therapy.

No unexpected toxicities were reported in the trial, and response rates exceed those of patients receiving rituximab based therapy alone.

For more on this trial, watch his interview with ecancer here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.